Lityum ya da karbamazepin kullanmakta olan ötimik bipolar I hastalarda protein kısıtlamasının mizaç ve plazma serotonin düzeyi üzerine etkileri

Amaç: Beyin serotoninin (5-HT), bipolar bozuklukta atakları da önleme dahil, lityum (Li) ya da karbamazepinin (KZ) etkilerine iştirak edip etmediği belli değildir. Bu çalışmanın amacı, Li ya da KZ kullanmakta olan ötimik bipolar I hastalarda protein kısıtlamasının mizaç ve serotonerjik sistem işlevi üzerindeki etkilerini araştırmaktı. Yöntem: Bipolar I bozukluk için DSM-IV kriterlerini dolduran 32 hasta ve 10 sağlıklı gönüllü bu çalışmaya dahil edildi. Hastalardan 22'si Li, 10'u KZ kullanmaktaydı. Bütün deneklere 1 hafta boyunca proteinden kısıtlı diyet uygulandı. Proteinden kısıtlı diyet öncesi ve sonrası plazma 5-HT ve serbest L-triptofan (L-TRF) düzeyleri ölçüldü. Diyet sonrası semptomlar yeniden değerlendirildi. Bulgular: Diyet sonrası plazma 5-HT düzeyinin Li grubunda kontrol grubuna göre önemli oranda azalmış olduğu bulundu. Hastaların mizaçlarında önemli bir değişme tespit edilmedi. Tartışma: Li ya da KZ tedavisi ile ötimik olan bipolar I hastalarda protein kısıtlamasının sebep olduğu 5-HT işlevindeki bozulma mizaç değişiklikleri oluşturmada yetersiz olabilir.

The effects of protein depletion on mood and plasma serotonin level in euthymic bipolar I patients treated with lithium or carbamazepine

Objective: It is not clear whether or not brain serotonin (5-HT) function mediates the therapeutic effects of lithium (Li) or carbamazepine (CZ) in bipolar disorder, including prevention of relapse. The aim of present study was to examine the effects of protein depletion on mood and serotonergic function in bipolar I patients who were symptomatically stable on Li or CZ. Method: Thirty-two patients who met DSM-IV criteria for bipolar I disorder and 10 healthy volunteers participated in this study. Twenty-two of the patients were on Li treatment while the others were on CZ. All subjects underwent a protein-depleted diet for 1 week. Plasma 5-HT and free L-tryptophan (L-TRP) levels were measured before and after the protein-depleted diet. Symptoms were also evaluated after the protein-depleted diet. Results: After the protein-depleted diet it was found that plasma 5-HT level of Li treated group was significantly lower than that of control group. There were no significant changes in mood. Conclusion: The disruption of 5-HT function caused by protein depletion may be insufficient to cause mood changes in bipolar I patients stabilized on Li or CZ treatment.

___

  • 1. Fernstrom JD, Hirsch MJ: Rapid repletion of brain serotonin in malnourished corn-fed rats following Ltryptophan injection. Life Sci 1975; 17:455-464.
  • 2. Bell C, Abrams J, Nutt D: Tryptophan depletion and its implications for psychiatry. Br J Psychiatry 2001;178:399-405.
  • 3. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR: Serotonin function and the mechanism of antidepressant action. Arch Gen Psychiatry 1990; 47:411-418.
  • 4. Salomon RM, Miller HL Delgado PL, Charney D: The use of tryptophan depletion to evaluate central serotonin function in depression and other neuropsychiatric disorders. Int Clin Psychopharmacol 1993; 8(suppl.2):41-46.
  • 5. Wood AJ, Goodwin GM: A review of the biochemical and neuropharmacological actions of lithium. Psychol Med 1987; 3:579-600.
  • 6. McCance SL, Cohen PR, Cowen PJ: Lithium increases 5- HT-mediated prolactin release. Psychopharmacology 1989; 99:279-281.
  • 7. Goodwin FK, Ghaemi SN: Understanding manicdepressive illness. Arch Gen Psychiatry 1998; 55:23-25.
  • 8. Cassidy F, Murry E, Carroll BJ: Tryptophan depletion in recently manic patients treated with lithium. Biol Psychiatry 1998; 43:230-232.
  • 9. Hughes JH, Dunne F, Young H: Effects of acute tryptophan depletion on mood and suicidal ideation in bipolar patients symptomatically stable on lithium. Br J Psychiatry 2000; 177:447-451.
  • 10. Cappiello A, Sernyak MJ, Malison RT, McDougle CJ, Heninger GR, Price LH: Effects of acute tryptophan depletion in lithium-remitted manic patients: A pilot study. Biol Psychiatry 1997; 42:1076-1078.
  • 11. Post RM, Uhde TW, Ballenger JC, Squillace KM: Prophylactic efficacy of carbamazepine in manic-depressive illness. Am J Psychiatry 1983; 140:1602-1604.
  • 12. Elphick M, Yang JD, Cowen PJ: Effects of carbamazepine on dopamine- and serotonin- mediated neuroendocrine responses. Arch Gen Psychiatry 1990;47:135-140.
  • 13. Akdemir A, Örsel S, Dağ İ, Türkçapar H, İşcan N, Özbay H: Hamilton depresyon derecelendirme ölçeğinin (HDDÖ) geçerliliği, güvenirliliği ve klinikte kullanımı. Psikiyatri Psikoloji Psikofarmakoloji Dergisi 1996; 4:251-259.
  • 14. Snaith RP, Baugh SJ, Clayden AD, Husain A, Sipple MA: The clinical anxiety scale: an instrument derived from the Hamilton Anxiety Scale. Br J Psychiatry 1982;141:518-523.
  • 15. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389.
  • 16. Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133:429-435.
  • 17. Traiffort E, Huber P, Tayeb N: Rapid determination of 5- hydroxytryptamine in whole blood by liquid chromatography with fluorimetric detection. J Chromatogr 1991;571:231-234.
  • 18. Price LH, Charney DS, Delgado PL, Heninger GR: Lithium and serotonin function: implications for the serotonin hypothesis of depression. Psychopharmacology 1990; 100:3-12.
  • 19. Young LT, Warsh JJ, Kish SJ, Shannak K, Hornykeiwicz O: Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder. Biol Psychiatry; 35:121-127.
  • 20. Shiah IS, Ko HC, Lee JF, Lu RB: Platelet 5-HT and plasma MHPG levels in patients with bipolar I and bipolar II depressions and normal controls. J Affect Disord 1999; 52:101-110.
  • 21. Blardi P, De Lalla A, Leo A, Auteri A, Iapichino S, Di Muro A ve ark.: Serotonin and fluoxetine levels in plasma and platelets after fluoxetine treatment in depressive patients. J Clin Psychopharmacol 2002; 22:131-136.
  • 22. Benkelfat C, Seletti B, Palmour RM, Hiller J, Ellenbogen M, Young S: Tryptophan depletion in stable lithiumtreated patients with bipolar disorder in remission. Arch Gen Psychiatry 1995; 52:154-156.
  • 23. Johnson L, El-Khoury A, Aberg-Wistedt A, Stain- Malmgren R, Mathe AA: Tryptophan depletion in lithium-stabilised patients with affective disorder. Int J Neuropsychopharmacol 2001; 4:329-336.